Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has granted Priority Review to cefiderocol (Shionogi) for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.
The supplemental New Drug Application includes data from the phase 3 APEKS-NP (Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Stenotrophomonas maltophilia in Nosocomial Pneumonia) trial, a double-blind, noninferiority study that evaluated the safety and efficacy of cefiderocol vs meropenem in patients with nosocomial pneumonia including HABP, VABP, and healthcare-associated bacterial pneumonia.
Patients were randomized to receive cefiderocol intravenously (IV) every 8 hours (n=145) or meropenem IV every 8 hours (n=146) for a period of 7-14 days, in addition to linezolid (to cover methicillin-resistant Staphylococcus aureus and Gram-positive bacteria). The primary efficacy outcome was all-cause mortality at day 14.
Results showed that at day 14, all-cause mortality in the modified intent-to-treat population was 12.4% for cefiderocol and 11.6% for meropenem (difference: 0.8, [95% CI, –6.6, 8.2]). As for safety, the incidence of treatment-emergent adverse events has found to be similar between the groups.
A Prescription Drug User Fee Act (PDUFA) target date of September 27, 2020 has been set for review of the application.
Cefiderocol, a novel siderophore cephalosporin, is marketed under the brand name Fetroja®. Fetroja is currently approved for the treatment of complicated urinary tract infections, including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex. The treatment is indicated for patients aged ≥18 years with limited or no alternative treatment options.
For more information visit shionogi.com.
